Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 4/2012

01.08.2012 | Invited Review

Novel options for the treatment of castration-resistant prostate cancer

verfasst von: Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian

Erschienen in: World Journal of Urology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.
Literatur
1.
Huggins C (1942) Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 115:1192–1200PubMedCrossRef
2.
Antonarakis ES, Eisenberger MA (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364:2055–2058PubMedCrossRef
3.
Heidenreich A, Bellmunt J, Bolla M et al (2010) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef
4.
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45PubMedCrossRef
5.
Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245PubMedCrossRef
6.
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520PubMedCrossRef
7.
Locke JA, Guns ES, Lubik AA et al (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407–6415PubMedCrossRef
8.
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRef
9.
Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822PubMedCrossRef
10.
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422PubMedCrossRef
11.
Edwards J, Krishna NS, Grigor KM, Bartlett JM (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552–556PubMedCrossRef
12.
Culig Z, Hoffmann J, Erdel M et al (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242–251PubMedCrossRef
13.
Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665–1671PubMedCrossRef
14.
Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168:2439–2443PubMedCrossRef
15.
Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMed
16.
Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506–2513PubMed
17.
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRef
18.
Galsky MD, Vogelzang NJ (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135–2144PubMedCrossRef
19.
Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670–3679PubMedCrossRef
20.
Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094PubMedCrossRef
21.
Auchus RJ (2001) The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 30:101–119 (vii)PubMedCrossRef
22.
Rowlands MG, Barrie SE, Chan F et al (1995) Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17, 20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem 38:4191–4197PubMedCrossRef
23.
Yap TA, Carden CP, Attard G, de Bono JS (2008) Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 8:449–457PubMedCrossRef
24.
Attard G, Reid AH, Olmos D, de Bono JS (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937–4940PubMedCrossRef
25.
Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563–4571PubMedCrossRef
26.
Ryan CJ, Smith MR, Fong L et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481–1488PubMedCrossRef
27.
Ryan CJ, Shah S, Efstathiou E et al (2011) Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17:4854–4861PubMedCrossRef
28.
Attard G, Reid AH, A’Hern R et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742–3748PubMedCrossRef
29.
Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489–1495PubMedCrossRef
30.
Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496–1501PubMedCrossRef
31.
Scher HI, Heller G, Molina A et al (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. ASCO Meet Abstr 29:LBA4517
32.
Matsunaga N, Kaku T, Ojida A et al (2004) C(17, 20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17, 20)-lyase inhibitors. Bioorg Med Chem 12:4313–4336PubMedCrossRef
33.
Dreicer R, Agus DB, MacVicar GR, MacLean D, ZhangT, Stadier WM (2010) Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study. Genitourin Cancer Symp Proc, abstract 103
34.
Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790PubMedCrossRef
35.
Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446PubMedCrossRef
36.
Inoue A, Yanagisawa M, Kimura S et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863–2867PubMedCrossRef
37.
Smollich M, Wulfing P (2007) The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 5:239–248PubMedCrossRef
38.
Nelson JB, Udan MS, Guruli G, Pflug BR (2005) Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7:631–637PubMedCrossRef
39.
Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M (2001) Expression of endothelin receptor a associated with prostate cancer progression. J Urol 165:1033–1036PubMedCrossRef
40.
Yin JJ, Mohammad KS, Kakonen SM et al (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100:10954–10959PubMedCrossRef
41.
Opgenorth TJ, Adler AL, Calzadilla SV et al (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473–481PubMed
42.
Carducci MA, Nelson JB, Bowling MK et al (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20:2171–2180PubMedCrossRef
43.
Samara E, Dutta S, Cao G et al (2001) Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol 41:397–403PubMedCrossRef
44.
Carducci MA, Padley RJ, Breul J et al (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679–689PubMedCrossRef
45.
Nelson JB, Love W, Chin JL et al (2008) Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113:2478–2487PubMedCrossRef
46.
Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959–1966PubMedCrossRef
47.
Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR (2006) Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 107:530–535PubMedCrossRef
48.
Armstrong AJ, Creel P, Turnbull J et al (2008) A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 14:6270–6276PubMedCrossRef
49.
Morris CD, Rose A, Curwen J et al (2005) Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92:2148–2152PubMedCrossRef
50.
James ND, Caty A, Borre M et al (2009) Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55:1112–1123PubMedCrossRef
51.
Nelson JB, Fizazi K, Miller K (2011) Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 29(suppl 7): abstr 117
52.
Nilsson S, Franzen L, Parker C et al (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8:587–594PubMedCrossRef
53.
Parker C (2011) Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a Phase III randomized trial (ALSYMPCA). The 2011 European multidisciplinary cancer congress. Stockholm: Eur J Cancer 47(Suppl 2):3
54.
Chi KN, Eisenhauer E, Fazli L et al (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97:1287–1296PubMedCrossRef
55.
Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247–4254PubMedCrossRef
56.
Chi KN, Siu LL, Hirte H et al (2008) A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14:833–839PubMedCrossRef
57.
Mita AC, Denis LJ, Rowinsky EK et al (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730PubMedCrossRef
58.
Pivot X, Koralewski P, Hidalgo JL et al (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547–1552PubMedCrossRef
59.
Shigeta K, Miura Y, Naito Y, Takano T (2011) Cabazitaxel for castration-resistant prostate cancer. Lancet 377:121 (author reply 122–123)PubMedCrossRef
Metadaten
Titel
Novel options for the treatment of castration-resistant prostate cancer
verfasst von
Carsten-H. Ohlmann
Axel S. Merseburger
Henrik Suttmann
David Schilling
Lutz Trojan
Carsten Kempkensteffen
Stefan Corvin
Michael J. Mathers
Patrick J. Bastian
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 4/2012
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-011-0796-7

Weitere Artikel der Ausgabe 4/2012

World Journal of Urology 4/2012 Zur Ausgabe

Topic paper

Surgical management of pelvic organ prolapse: abdominal and vaginal approaches

Topic paper

Pelvic floor muscle training in treatment of female stress urinary incontinence, pelvic organ prolapse and sexual dysfunction

Original Article

GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy

Original Article

Clinical characteristics, nocturnal antidiuretic hormone levels, and responsiveness to DDAVP of school children with primary nocturnal enuresis

Topic paper

Failures and complications in pelvic floor surgery

Original Article

Tyrosine kinase expression profile in clear cell renal cell carcinoma

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise